Are weight-loss peptides a treat, or is the marketing playing tricks? 🎃 In this Halloween episode of The Peptide Effect, we explore AOD-9604, cagrilintide, semaglutide, tirzepatide, and retatrutide—unmasking their differences and separating promising research from spooky sales pitches.

From food noise and fullness to fat-loss claims and peptide stacks, we shine a flashlight on what the evidence shows, what remains uncertain, and why stronger appetite suppression is not always better. Expect science, Halloween humor, and a reminder that enjoying a little candy does not require a metabolic exorcism.

For education and entertainment only. This episode is not medical advice; some compounds discussed are investigational or not approved for weight management.

CBL-514 is making waves in fat-reduction research, but despite showing up in peptide conversations, it isn’t a peptide. In this episode of The Peptide Effect, we explain what it is, how it differs from AOD-9604, and how peptides like tesamorelin, semaglutide, tirzepatide, and retatrutide fit into the discussion. Discover the differences between targeted fat reduction, visceral fat reduction, and overall weight loss—and what the research actually supports.

What if GLP-1 drugs are doing more than controlling blood sugar and reducing appetite?

In this episode of The Peptide Effect, we break down a 2026 study revealing a newly identified molecular “switch” involving Med14, a protein that helps regulate gene transcription inside pancreatic beta cells. Researchers found that sustained GLP-1 receptor signaling may activate broader gene programs tied to beta-cell function, metabolism, and viability.

We’ll explain what Med14 is, what phosphorylation means, how GLP-1 signals travel from the cell surface to the nucleus, and why this discovery could matter for the future of metabolic medicine. We’ll also separate what the study actually found from the exaggerated claims you may see online, including whether GLP-1 drugs permanently “reprogram” the pancreas.

A fascinating look at what may be happening beneath the surface of GLP-1 therapy, far beyond appetite suppression and weight loss.